1EHRENSTEIN MR, EVANS JG, SINGH A, et al. Compro- mised function ofregulatory teells in rheumatoid arthritis and reversal by anti-IN-Falpha thempy[J]. J Exp Med, 2004,200 (3) :277 285.
2LIU MF, WANG CR, FANG LI, et al. Decreased CDZ cD tcels inperipheral blood of patients with systemic lupus ery- thematosusf [J]. Immunol,2004,59(2) : 198 202.
4PICCIRILLO CA, SHEVACH EM. Cutting edge: control of CD8+ T cell activation by CD4+ CD25+ immunoregulatory cells[J]. Immunol,2001,167(3) :137-140.
5ZELENIKA D,DAMSE, UMM S, et al. The role of CD4+ T cell subsets in determining transplantation rejection or toler- ance[J]. Immunol Rev,2001,182(8) : 164-179.
6WOOD KJ, SAKAGUCHI S. Regulatory T ceils in transplan- tation tolerance[J]. Nat Rev Immunol,2003,a(3) : 199-206.
7MATSUSHITA N, PILON THOMAS S A, Martini. M, et al. Comparative methodologies of regulatory T cell depletion in a murinemelanoma model[J]. J Immunol Methods, 2008, 333(12) :167-179.
8YANG Y,PAIK J H,CHO D,et al. Resveratml induces the suppression oftumor-derived CD4 CD25 regulatory Tcells[J]. Int Immunopharmacol, 2008,8(4) : 542-547.
9PHAN G Q,YANG J C,SHERRY R M,et al. Cancer regres- sion and autoimmunityinduced by cytotoxic T lymphocyte-as- sociated antigen 4 blockade in patients with metastatic mela- noma[J]. Proc NatlAcad Sci USA, 2003,100(14):8 372-8 377.
二级参考文献10
1Levings MK, Sangregorio R, Roncarolo MG. Human cd25 ( + )cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med, 2001,193 : 1295-1302.
2Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest, 2002,109 : 131-140.
3Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun, 2003,21 : 273-276.
4Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4 + CD25 high regulatory cells in human peripheral blood. J Immunol, 2001,167 :1245-1253.
5Can D, Malmstrom V, Baecher-Allan C, et al. Isolation and functional characterization of regulatory CD25^bright CD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol,2003,33:215-223.
6Kuniyasu Y, Takahashi T, hoh M, et al. Naturally anergic and suppressive CD25 ( + ) CD4 ( + ) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation, Int Immuno1,2000,12 : 1145-1155.
7Seo SJ, Fields ML, Buckler JL, et al. The impact ofT helper and T regulatory cells on the regulation of anti-double-stranded DNA Bcells. Immunity, 2002,16:535-546.
8Dieckmann D, Plottner H, Berchtold S, et al. Ex vivo isolation and characterization of CD4 ( + ) CD25 ( + ) T cells with regulatory properties from human blood. J Exp Med,2001,193 :1303-1310.
9Stephens LA, Mottet C, Mason D, et al. Human CD4 ( + )CD25( + ) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol,2001,31:1247-1254.
10Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDA1. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum,1992,35:630-640.
